The Clinical Use of Genomic Profiling for Prognosis Prediction in High Grade Serous Ovarian Cancer

I Nyoman Bayu Mahendra; Fransiskus Rendy; Pande Prayudi

doi:10.3889/oamjms.2023.11199

Authors

I Nyoman Bayu Mahendra Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Faculty of Medicine, Udayana University, Prof. dr. I Gusti Ngoerah Gde Ngoerah General Hospital, Denpasar, Bali, Indonesia https://orcid.org/0000-0001-9336-8186
Fransiskus Rendy Department of Obstetrics and Gynecology, Faculty of Medicine, Udayana University, Prof. dr. I Gusti Ngoerah Gde Ngoerah General Hospital, Denpasar, Bali, Indonesia https://orcid.org/0000-0002-6412-6687
Pande Prayudi Department of Obstetrics and Gynecology, Faculty of Medicine, Udayana University, Prof. dr. I Gusti Ngoerah Gde Ngoerah General Hospital, Denpasar, Bali, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2023.11199

Keywords:

Epithelial ovarian carcinoma, Genetic profiles, Prognosis

Abstract

The majority of ovarian cancer cases are high-grade serous ovarian cancers (HGSOC). HGOSC harbors several genomic alterations that play crucial roles in carcinogenesis. Studies on the molecular characterization of HGSOC have suggested that HGSOC is a heterogenous disease, rather than a singular disease entity. Genomic profiling using gene expressions, methylation patterns, and non-coding RNA expression patterns have all been used as the basis for the molecular categorization of HGSOC. Understanding these classifications in relationship to the prognosis, such as overall survival, progression-free survival, and response to chemotherapy, is crucial in the age of precision medicine in order to direct specialized or targeted treatment and improve the prognosis. Research in the future will concentrate on creating therapies targeted at certain molecular subtypes.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High-grade serous ovarian cancer: Basic sciences, clinical and therapeutic standpoints. Int J Mol Sci. 2019;20(4):952. https://doi.org/10.3390/ijms20040952 PMid:30813239

Khashaba M, Fawzy M, Abdel-Aziz A, Eladawei G, Nagib R. Subtyping of high grade serous ovarian carcinoma: Histopathological and immunohistochemical approach. J Egypt Natl Canc Inst. 2022;34(1):6. https://doi.org/10.1186/s43046-022-00104-9 PMid:35138498

Wang J, Li J, Chen R, Yue H, Li W, Wu B, et al. DNA methylation-based profiling reveals distinct clusters with survival heterogeneity in high-grade serous ovarian cancer. Clin Epigenetics. 2021;13(1):190. https://doi.org/10.1186/s13148-021-01178-3 PMid:34645493

Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-15. https://doi.org/10.1038/nature10166 PMid:21720365

Cheng Z, Mirza H, Ennis DP, Smith P, Gavarró LM, Sokota C, et al. The genomic landscape of early-stage ovarian high-grade serous carcinoma. Clin Cancer Res. 2022;28(13):2911-22. https://doi.org/10.1158/1078-0432.CCR-21-1643 PMid:35398881

Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198-208. https://doi.org/10.1158/1078-0432.CCR-08-0196 PMid:18698038

Hollis RL, Meynert AM, Michie CO, Rye T, Churchman M, Hallas-Potts A, et al. Multiomic characterization of high-grade serous ovarian carcinoma enables high-resolution patient stratification. Clin Cancer Res. 2022;28(16):3546-56. https://doi.org/10.1158/1078-0432.CCR-22-0368 PMid:35696721

Konishi I, Abiko K, Hayashi T, Yamanoi K, Murakami R, Yamaguchi K, et al. Peritoneal dissemination of high-grade serous ovarian cancer: Pivotal roles of chromosomal instability and epigenetic dynamics. J Gynecol Oncol. 2022;33(5):e83. https://doi.org/10.3802/jgo.2022.33.e83 PMid:36032027

Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst. 2014;106(10):dju249. https://doi.org/10.1093/jnci/dju249 PMid:25269487

Wang C, Armasu SM, Kalli KR, Maurer MJ, Heinzen EP, Keeney GL, et al. Pooled clustering of high-grade serous ovarian cancer gene expression leads to novel consensus subtypes associated with survival and surgical outcomes. Clin Cancer Res. 2017;23(15):4077-85. https://doi.org/10.1158/1078-0432.CCR-17-0246 PMid:28280090

Shilpi A, Kandpal M, Ji Y, Seagle BL, Shahabi S, Davuluri RV. Platform-independent classification system to predict molecular subtypes of high-grade serous ovarian carcinoma. JCO Clin Cancer Inform. 2019;3:1-9. https://doi.org/10.1200/CCI.18.00096 PMid:31002564

Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013;123(1):517-25. https://doi.org/10.1172/JCI65833 PMid:23257362

Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, et al. Copy number signatures and mutational processes in ovarian carcinoma. Nat Genet. 2018;50(9):1262-70. https://doi.org/10.1038/s41588-018-0179-8 PMid:30104763

Hillman RT, Chisholm GB, Lu KH, Futreal PA. Genomic rearrangement signatures and clinical outcomes in high-grade serous ovarian cancer. J Natl Cancer Inst. 2017;110(3):265-72. https://doi.org/10.1093/jnci/djx176 PMid:29584920

Sohn MH, Kim SI, Shin JY, Kim HS, Chung HH, Kim JW, et al. Classification of high-grade serous ovarian carcinoma by epithelial-to-mesenchymal transition signature and homologous recombination repair genes. Genes (Basel). 2021;12(7):1103. https://doi.org/10.3390/genes12071103 PMid:34356119

Xu L, Wu Y, Che X, Zhao J, Wang F, Wang P, et al. Cox-Lasso analysis reveals a ten-lncrna signature to predict outcomes in patients with high-grade serous ovarian cancer. DNA Cell Biol. 2019;38(12):1519-28. https://doi.org/10.1089/dna.2019.4826 PMid:31657627

Zheng M, Mullikin H, Hester A, Czogalla B, Heidegger H, Vilsmaier T, et al. Development and validation of a novel 11-gene prognostic model for serous ovarian carcinomas based on lipid metabolism expression profile. Int J Mol Sci. 2020;21(23):9169. https://doi.org/10.3390/ijms21239169 PMid:33271935

Wang S, Wang X, Xia X, Zhang T, Yi M, Li Z, et al. Identification of the immune subtype of ovarian cancer patients by integrated analyses of transcriptome and single-cell sequencing data. Sci Rep. 2022;12(1):13296. https://doi.org/10.1038/s41598-022-17645-7 PMid:35918500

Lu X, Ji C, Jiang L, Zhu Y, Zhou Y, Meng J, et al. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy. Cell Prolif. 2021;54(3):e12979. https://doi.org/10.1111/cpr.12979 PMid:33522069

Murakami R, Matsumura N, Mandai M, Yoshihara K, Tanabe H, Nakai H, et al. Establishment of a novel histopathological classification of high-grade serous ovarian carcinoma correlated with prognostically distinct gene expression subtypes. Am J Pathol. 2016;186(5):1103-13. https://doi.org/10.1016/j.ajpath.2015.12.029 PMid:26993207

Olbrecht S, Busschaert P, Qian J, Vanderstichele A, Loverix L, Van Gorp T, et al. High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: Specific cell subtypes influence survival and determine molecular subtype classification. Genome Med. 2021;13(1):111. https://doi.org/10.1186/s13073-021-00922-x PMid:34238352

Wu Y, Xia L, Zhao P, Deng Y, Guo Q, Zhu J, et al. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer. Aging (Albany NY). 2020;12(12):11398-415. https://doi.org/10.18632/aging.103199 PMid:32544083

Davis S, Sheppard KE, Anglesio MS, George J, Traficante N, Fereday S, et al. Enhanced GAB2 expression is associated with improved survival in high-grade serous ovarian cancer and sensitivity to PI3K inhibition. Mol Cancer Ther. 2015;14(6):1495-503. https://doi.org/10.1158/1535-7163.MCT-15-0039 PMid:25852062

Li M, Cheng X, Rong R, Gao Y, Tang X, Chen Y. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer. BMC Cancer. 2020;20(1):1032. https://doi.org/10.1186/s12885-020-07541-6 PMid:33109151

Kang H, Choi MC, Kim S, Jeong JY, Kwon AY, Kim TH, et al. USP19 and RPL23 as candidate prognostic markers for advanced-stage high-grade serous ovarian carcinoma. Cancers (Basel). 2021;13(16):3976. https://doi.org/10.3390/cancers13163976 PMid:34439131

Choi J, Topouza DG, Tarnouskaya A, Nesdoly S, Koti M, Duan QL. Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer. BMC Cancer. 2020;20(1):413. https://doi.org/10.1186/s12885-020-06922-1 PMid:32404140

Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, Agarwal R, et al. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res. 2011;71(13):4412-22. https://doi.org/10.1158/0008-5472.CAN-10-4111 PMid:21571862

Weberpals JI, Pugh TJ, Marco-Casanova P, Goss GD, Wright NA, Rath P, et al. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer. Cancer Med. 2021;10(9):3045-58. https://doi.org/10.1002/cam4.3831 PMid:33811746

Shih I, Nakayama K, Wu G, Nakayama N, Zhang J, Wang T. Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma. Mod Pathol. 2011;24(5):638-45. https://doi.org/10.1038/modpathol.2010.230 PMid:21240255

Kang HJ, Chun SM, Kim KR, Sohn I, Sung CO. Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma. PLoS One. 2013;8(8):e72609. https://doi.org/10.1371/journal.pone.0072609 PMid:23967324

Ganapathi MK, Jones WD, Sehouli J, Michener CM, Braicu IE, Norris EJ, et al. Expression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high-grade serous ovarian cancer. Int J Cancer. 2015;138(3):679-88. https://doi.org/10.1002/ijc.29815 PMid:26311224

Fang L, Wang H, Li P. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer. Invest New Drugs. 2017;36(2):187-94. https://doi.org/10.1007/s10637-017-0523-3 PMid:29082457